- Home
- CVKD vs KAPA Comparison
CVKD vs KAPA Comparison
Compare CVKD & KAPA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVKD
- KAPA
- Stock Information
- Founded
- CVKD 2022
- KAPA 2013
- Country
- CVKD United States
- KAPA United States
- Employees
- CVKD N/A
- KAPA N/A
- Industry
- CVKD Medicinal Chemicals and Botanical Products
- KAPA
- Sector
- CVKD Health Care
- KAPA
- Exchange
- CVKD Nasdaq
- KAPA NYSE
- Market Cap
- CVKD 26.3M
- KAPA 21.3M
- IPO Year
- CVKD 2023
- KAPA 2024
- Fundamental
- Price
- CVKD $14.01
- KAPA $1.48
- Analyst Decision
- CVKD Strong Buy
- KAPA Strong Buy
- Analyst Count
- CVKD 2
- KAPA 1
- Target Price
- CVKD $46.00
- KAPA $9.00
- AVG Volume (30 Days)
- CVKD 70.3K
- KAPA 720.9K
- Earning Date
- CVKD 11-07-2024
- KAPA 11-14-2024
- Dividend Yield
- CVKD N/A
- KAPA N/A
- EPS Growth
- CVKD N/A
- KAPA N/A
- EPS
- CVKD N/A
- KAPA N/A
- Revenue
- CVKD N/A
- KAPA N/A
- Revenue This Year
- CVKD N/A
- KAPA N/A
- Revenue Next Year
- CVKD N/A
- KAPA N/A
- P/E Ratio
- CVKD N/A
- KAPA N/A
- Revenue Growth
- CVKD N/A
- KAPA N/A
- 52 Week Low
- CVKD $5.40
- KAPA $1.22
- 52 Week High
- CVKD $32.55
- KAPA $4.00
- Technical
- Relative Strength Index (RSI)
- CVKD 43.74
- KAPA N/A
- Support Level
- CVKD $15.52
- KAPA N/A
- Resistance Level
- CVKD $19.97
- KAPA N/A
- Average True Range (ATR)
- CVKD 1.80
- KAPA 0.00
- MACD
- CVKD -0.44
- KAPA 0.00
- Stochastic Oscillator
- CVKD 0.17
- KAPA 0.00
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is focused on developing a novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (on dialysis) and atrial fibrillation (irregular heartbeat) or AFib. Tecarfarin is an anticoagulant designed using a drug design process that targets a different pathway than most commonly prescribed drugs for the treatment of thrombosis and AFib.
About KAPA KAIROS PHARMA LTD
Kairos Pharma Ltd is a clinical-stage biopharmaceutical company. It is engaged in therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma.